|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
|
3.1 Tabac
|
|
|
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5.2 Pharma
|
|
|
US 'orphan status' for Immunocore's eye cancer drug [PharmaTimes]
|
|
|
|
|
|
The
firm is hoping that IMCgp100, its most advanced ImmTAC (Immune
mobilising mTCR Against Cancer), will offer patients the first treatment
for the debilitating condition, and says the orphan drug designation
gives it the opportunity to fast-track the programme.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
Merck, Affimed to test Hodgkin lymphoma combo [Pharma Times]
|
|
|
|
|
|
Under
the deal, Affimed will fund and conduct a Phase Ib clinical trial to
assess the potential of combining Merck's anti-PD-1 therapy Keytruda
(pembrolizumab) with Affimed's experimental AFM13 for the treatment of
patients whose disease has relapsed or is refractory to chemotherapy.
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
Big Pharma’s worst nightmare [The Guardian]
|
|
|
|
|
|
Jamie
Love has spent years battling global drug companies, unshakable in his
belief that even the world’s poorest people should have access to
life-saving medicines. Is it time that our own government listened to
him?
|
|
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
5.5 ASCO
|
|
|
|
6. Lutte contre les cancers
|
|
|
NCI-Match extends pause in enrollment [BioCentury]
|
|
|
|
|
|
According
to NCI's ECOG-ACRIN group, the delay will allow the study's leaders to
expand laboratory capabilities to accommodate the volume and pace of
patient enrollment, add treatment arms and complete a scientific review
of data from the first set of patients.
|
|
|
|
|
|
|
|
|
6.6 Publications
|
|
|
Top journal editors resist transparency [HealthNewsReview]
|
|
|
|
|
|
Journal
editors certainly have conflicted interests of their own, an obvious
one being the huge revenues generated by pharmaceutical company ads and
reprints. One is hard pressed to find evidence showing transparency and
sharing in science to be a bad thing for anyone without marketing
interests.
|
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.7.2 Applis
|
|
|
EU Looks to Improve Data Quality of mHealth Apps [RAPS]
|
|
|
|
|
|
The
European Commission is bringing together a working group to develop
guidelines by the end of 2016 for assessing the validity and reliability
of the data that mobile health (mHealth) applications collect and
process in order to make these ubiquitous apps more useful for public
health.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|